Targeted immunomodulation with CD44-targeting nanovaccine enhances antitumor immunity in melanoma through TLR7/8 and TLR3 agonists.
- DOI
- 10.1039/d6bm01033d
- Published
- 2026 Sep 11
- Container
- Biomaterials science
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1039/d6bm01033d,
title = {Targeted immunomodulation with CD44-targeting nanovaccine enhances antitumor immunity in melanoma through TLR7/8 and TLR3 agonists.},
author = {Pillarisetti S and Sathiyamoorthy P and Jung TY and Uthaman S and Park IK},
year = {2026},
journal = {Biomaterials science},
doi = {10.1039/d6bm01033d},
url = {https://doi.org/10.1039/d6bm01033d}
}RIS
TY - JOUR TI - Targeted immunomodulation with CD44-targeting nanovaccine enhances antitumor immunity in melanoma through TLR7/8 and TLR3 agonists. AU - Pillarisetti S AU - Sathiyamoorthy P AU - Jung TY AU - Uthaman S AU - Park IK PY - 2026 JO - Biomaterials science DO - 10.1039/d6bm01033d UR - https://doi.org/10.1039/d6bm01033d ER -
APA
S, P., P, S., TY, J., S, U., & IK, P. (2026). Targeted immunomodulation with CD44-targeting nanovaccine enhances antitumor immunity in melanoma through TLR7/8 and TLR3 agonists.. Biomaterials science. https://doi.org/10.1039/d6bm01033d
Source records
- pubmed · retrieved 2026-09-27T01:00:20.777Z